BioCentury
ARTICLE | Clinical News

Pfizer's Ibrance shows PFS benefit in PALOMA-3

June 2, 2015 1:44 AM UTC

In the Phase III PALOMA-3 study, Ibrance palbociclib from Pfizer Inc. (NYSE:PFE) more than doubled progression-free survival (PFS) in patients with estrogen receptor-positive, epidermal growth factor receptor 2 ( HER2)-negative metastatic breast cancer. The study, which Pfizer said in April was stopped early after it met its primary endpoint, compared Ibrance plus Faslodex fulvestrant with Faslodex alone in women whose cancer that had relapsed or progressed after endocrine therapy.

Patients receiving the Ibrance combo had a median PFS of 9.2 months vs. 3.8 months among those receiving Faslodex alone (HR=0.422, 95% CI: 0.318, 0.560, p<0.000001). ...